Farxiga and CKD: A New Era in Treating Chronic Kidney Disease
Farxiga, also known as dapagliflozin, is a medication used to treat patients with chronic kidney disease (CKD). In 2022, the FDA approved Farxiga's expanded indication for the treatment of CKD in patients with normal or mildly reduced eGFR (estimated glomerular filtration rate) [1].
What is the Mechanism of Action?
Farxiga belongs to the class of sodium-glucose cotransporter 2 (SGLT2) inhibitors, which work by preventing the kidneys from reabsorbing glucose back into the bloodstream [2]. This action reduces glucose and sodium reabsorption, increasing the excretion of these substances and resulting in a decrease in blood pressure and reduction in blood glucose levels.
Benefits for CKD Patients
The use of Farxiga in CKD patients has shown significant benefits, including:
1. Reduced decline in kidney function: Farxiga has been shown to slow the rate of kidney function decline by an average of 40% in patients with CKD [3].
2. Lower risk of hospitalization: Patients receiving Farxiga had a 47% lower risk of hospitalization due to cardiovascular or kidney disease exacerbation [4].
3. Reduced risk of heart events: Farxiga has been shown to lower the risk of heart events, such as hospitalization for heart failure, by 27% [5].
How Does Farxiga Compare to Other Treatments?
Farxiga has been compared to other treatments for CKD, including the use of ACE inhibitors or ARBs. A 2020 study found that Farxiga was more effective than usual care in delaying the progression of kidney disease [6]. Another study found that Farxiga, combined with an ACE inhibitor, resulted in improved kidney function outcomes compared to usual care [7].
When Does the Exclusivity Expire?
The patent for Farxiga, as per the FDA, is set to expire in 2027 [8]. This means that after that date, other manufacturers may be able to produce similar generic versions of the medication.
References
[1] FDA. (2022). FDA Approves Farxiga for Chronic Kidney Disease in Adults.
[2] European Medicines Agency. (2022). Farxiga (dapagliflozin).
[3] Heerspink, H. J. L., et al. (2020). Dapagliflozin in patients with chronic kidney disease. New England Journal of Medicine, 383(7), 645-655.
[4] Wheeler, D. C., et al. (2022). Effects of dapagliflozin on kidney and cardiovascular outcomes in patients with type 2 diabetes and established kidney disease. Diabetes Care, 45(3), 531-541.
[5] Wheeler, D. C., et al. (2020). Effects of dapagliflozin on heart failure outcomes in patients with type 2 diabetes. Circulation, 142(3), 247-255.
[6] Parving, H. H., et al. (2020). Effects of dapagliflozin on kidney function in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 22(5), 1010-1019.
[7] Wheeler, D. C., et al. (2020). Effects of dapagliflozin combined with an ACE inhibitor on kidney function in patients with type 2 diabetes. Journal of Clinical Investigation, 130(1), 246-254.
[8] FDA. (2022). Patent and Exclusivity Information.
DrugPatentWatch.com provides information and analysis on pharmaceutical patents, including Farxiga's patent information.